Glumetza Patent Settlement Without An Authorized Generic Plus Price Hike Spawns Litigation
Executive Summary
Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.
You may also be interested in...
Brand-Generic Pay-For-Delay Deals May Become Extinct, FTC Finds
Only one of 232 brand-generic patent suit settlements in the US during FY 2016 contained a side deal or commitment not to market an authorized generic.
Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.
Insulin Pricing, PBM Relationships Under Government Microscope
Minnesota Attorney General demands Novo Nordisk and Sanofi provide information on their insulin pricing; they are also among several companies facing probes over their contracts with pharmacy benefit managers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: